Wiley, Journal of Internal Medicine, 6(291), p. 864-869, 2022
DOI: 10.1111/joim.13453
Full text: Unavailable
AbstractBackgroundPost‐marketing pharmacovigilance data are scant on the safety of Covid‐19 vaccines among people with previous SARS‐CoV‐2 infection compared with ordinary vaccine recipients. We compared the post‐vaccination adverse events of special interests (AESI), accident and emergency room (A&E) visit, and hospitalization between these two groups.MethodsWe conducted a retrospective cohort study using a territory‐wide public healthcare database with population‐based vaccination records in Hong Kong.ResultsIn total, 3922 vaccine recipients with previous SARS‑CoV‑2 infection and 1,137,583 vaccine recipients without previous SARS‑CoV‑2 infection were included. No significant association was observed between previous SARS‑CoV‑2 infection and AESI or hospitalization. Previous SARS‑CoV‑2 infection was significantly associated with a lower risk of A&E visit (CoronaVac: hazard ratios [HR] = 0.56, 95% confidence intervals [CI]: 0.32–0.99; Comirnaty: HR = 0.62, 95% CI: 0.47–0.82).ConclusionNo safety signal of Covid‐19 vaccination was detected from the comparison between vaccine recipients with previous SARS‐CoV‐2 infection and those without infection.